Diffuse Scleroderma clinical trials at UCSF

2 research studies open to eligible people

Diffuse scleroderma makes skin and organs stiff and hard. UCSF is researching a new medicine for lung problems related to scleroderma. At UCSF, there's another trial looking at a novel therapy for people with extensive skin issues from scleroderma.

Showing trials for

  • BMS-986278 in Participants With Progressive Pulmonary Fibrosis

    open to eligible people ages 21 years and up

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

    San Francisco, California and other locations

  • Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

    open to eligible people ages 18-65

    The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

    San Francisco, California and other locations

Last updated: